1TT
0.002
100%
ASR
0.002
-33.3%
RLG
0.006
50%
CR9
0.002
-33.3%
AVR
7.5
33.5%
CRR
0.003
-25%
SBR
0.008
33.3%
ERL
0.004
-20%
SRN
0.004
33.3%
RGL
0.004
-20%
CAV
0.005
25%
SVY
0.012
-20%
TNC
0.24
23.1%
CMG
0.11
-18.5%
SRK
0.039
21.9%
AQX
0.005
-16.7%
AUR
0.006
20%
IPT
0.005
-16.7%
NVO
0.12
20%
GT1
0.032
-15.8%
HMX
0.025
19%
OLY
0.045
-15.1%
M24
0.013
18.2%
SCN
0.017
-15%
VHL
0.039
18.2%
GDG
4.13
-14.8%
CYM
0.02
17.6%
PCL
0.006
-14.3%
DTR
0.007
16.7%
WMG
0.13
-13.3%
FFF
0.007
16.7%
CDR
0.02
-13%
GLL
0.007
16.7%
OLH
0.04
-13%
HHR
0.007
16.7%
ADO
0.007
-12.5%
MKL
0.007
16.7%
ID8
0.007
-12.5%
REZ
0.028
16.7%
LYK
0.014
-12.5%

The Stock Network

The Stock Network (TSN) is your trusted source for ASX stock market news, key trends, and investment insights. Stay tuned for the latest reports, expert market analysis, and IPO updates.

ASX & US stock news headlines

TruScreen Group (NZX/ASX:TRU) has launched a 5-year program to screen 260,000 women for cervical cancer using its AI-enabled, real time, non-invasive, cervical cancer screening device. 

🩺The 5-year cervical cancer screening program was launched in Ho Chi Minh City on 12 April 2025, aiming to screen 260,000 women. 
🩺 The program uses TruScreen’s AI-enabled, real-time, non-invasive screening device, eliminating the need for lab infrastructure.
🩺 Partnership between TruScreen, Ho Chi Minh City Public Health Association and Gorton Health Services supports Vietnam’s goal to screen 60% of women aged 30-54. 

 
"This program with its target of screening 260,000 women may save the lives of over 2,600 mothers, daughters, sisters, wives and friends.” Marty Dillon, CEO of TruScreen
NeuroScientific Biopharmaceuticals (ASX:NSB) has acquired the patented StemSmartTMstem cell technology from Isopogen WA to deliver potent and clinically promising cellular medicine for immune-related diseases.

 

🔬Exclusive rights secured to patented StemSmartTM stem cell technology for treating inflammatory and immune-related diseases

🔬StemSmartTM interacts with immune system to modulate immune responses

🔬Strong early trial results in patients with Crohn’s disease and other serious conditions, with multiple positive clinical responses

 

 “We’re incredibly excited to add mesenchymal stem cell technology to our growing portfolio. This acquisition not only complements our existing pipeline of therapeutic peptides, but also strategically positions us at the forefront of next-generation biologics.” – Dr Anton Uvarov, Founding Director of NeuroScientific
AML3D Limited (ASX:AL3) has announced the largest custom ARCEMY® system ever built. The system was installed at the US Navy’s AM Center of Excellence in Danville VA, that has been setup and operated by Austal USA. Bringing the system online triggers payment of the final 50% of the contract value. 

🇺🇲 The custom ARCEMY® system supports Austal USA’s drive to further embed additive manufacturing into the U.S. Navy’s supply chain.
🇺🇲 Austal USA leads and operates the Navy’s Additive Manufacturing Center of Excellence in Danville, Virginia, which currently operates a large scale ARCEMY® 6700 system delivered in early 2024.
🇺🇲 A second custom ARCEMY® system was recently installed, featuring a massive 11,000kg positioner and over four meters of linear rail, enabling a build volume of approximately 35 cubic meters—making it the largest of its kind

“The successful delivery the custom ARCEMY® system to Austal USA (refer to ASX announcement November 20,2023) aligns with our ambitions to expand the range of U.S.
defense work we do. AML3D already has a track record of deploying our WAM Additive Manufacturing technology in support of the U.S. Navy submarine industrial base. Those successes are translating to an adoption of additive manufacturing technology in the wider U.S. Marine Industrial Base, covering shipbuilding and munitions". - Sean Ebert, AML3D CEO
Neuren Pharmaceuticals (ASX:NEU) has secured FDA confirmation of primary endpoints for its Phase 3 clinical trial of a new drug therapy to treat Phelan-McDermid Syndrome (PMS). 

🧬 Between 8,000-15,000 have PMS, and there are no medication, drugs or therapies to treat it, causing an overwhelming unmet medical need

🧬 PMS affects a region of chromosome 22 that supports synapses in the brain, severely impacting quality of life 

🧬 Neuren’s trial which commences in mid-2025 marks the first ever Phase 3 trial for PMS in children

“We are very pleased with the outcome of another constructive discussion with the FDA and are now excited to be able to move forward as planned with the first ever Phase 3 trial in children with Phelan-McDermid syndrome.” – Jon Pilcher, CEO of Neuren
Australian game developer Streamplay Studio (ASX:SP8) has reported strong first-quarter performance, with its subsidiary Noodlecake generating $2.7M in revenue and preparing to launch several high-profile games.

 Subsidiary Noodlecake generated $2.7M revenue in Q1 following acquisition by Streamplay on 1 January 2025
 Upcoming mobile title Super Flappy Golf has achieved over 50,000 pre-orders
 Over 30 new game pitches and strategic partnerships explored at Game Developers Conference (GDC) 2025

“We’ve been very pleased with how seamlessly the Noodlecake team has integrated, and we’re now strongly focused on driving growth both organically and through the
identification of complementary assets to bring into the group.” — Bert Mondello, Chairman of Streamplay Studio
Kincora Copper Limited (TSXV:KCC, ASX:KCC) has secured its second major earn-in with AngloGold Ashanti (JSE:ANG; NYSE:AU).The deal opens the way for more extensive exploration in the Northern Junee-Narromine Belt of the Macquarie Arc, Central West NSW, Australia.

⛏️ Multiple-year deal for the Nyngan South, Nevertire South and Mulla projects
⛏️ AngloGold Ashanti may earn a 70% interest by spending $25 million
⛏️Kincora remains the operator, receiving a 10% management fee

“We are very pleased to broaden our partnership with AngloGold Ashanti. It comes as we continue to progress our ongoing exploration program at the Nyngan project, with a ground gravity survey and hole twelve of the scout drilling program recently completed." - Kincora Copper Technical Committee chair, John Holliday and VP of Exploration Peter Leaman
The USA’s status as a global super-power is under the microscope and Teaminvest Private Group (ASX:TIP) CEO Andrew Coleman identifies where to invest as USA’s economic power wanes:

📉 Recession reality: TIP believes the US recession is no longer looming; it's arrived and says "Liberation Day" may go down as the moment things truly unraveled.

🛠️ People and productivity: Since the 16th century, growth has come from more workers or more output per worker and TIP says shrinking the workforce and blocking innovation breaks that math.

🌪️ Defying economic gravity: TIP warns policies that ignore fundamentals might seem bold, but gravity doesn’t care if you believe in it, it happens.
What is the VIX, and why does it spike during a crash?

#finance #fintok #stocks #shares #investing #wallstreet #VIX #fear #trump #trumptariffs

ASX announcement news

TMS

ORN

RLF

CAE

HGO

BMT

NAN

COV

HZR

Sharing stock market news

Raiz Invest (ASX:RZI): Helping Aussies create wealth by saving, investing and financial literacy

Auric Mining (ASX:AWJ): Advancing Jeffreys Find project by mining gold in WA’s heralded Goldfields

Listing on stock exchanges

Stock & market analysis.

FinTok

Stock & market analysis

IPOs

Listing on stock exchanges

Resources stocks & mining stocks

ASX 200

Last Update: 24-04-2025
Today's Date: 2025-04-25
Market Status: Closed
Last Update: 24-04-2025

Top Gainers

1TT0.002 100%
RLG0.006 50%
AVR7.5 33.5%
SBR0.008 33.3%

Biggest Losers

ASR0.002 -33.3%
CR90.002 -33.3%
CRR0.003 -25%
ERL0.004 -20%

By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy